Genomics England has enlisted a startup maker of artificial intelligence in a long-term partnership meant to increase patient access to immunotherapies, monitor treatment effectiveness, and identify resistance to these advanced cancer drugs.
Cambridge Cancer Genomics — known as CCG.ai — is joining the Discovery Forum, a Genomics England-led collaboration platform for genomics researchers in the UK. CCG.ai also will contribute its liquid biopsy technology and a sequencing panel that measures tumor mutational burden to assess treatment resistance to immunotherapy drugs.
“Through genomic analysis of longitudinal liquid biopsy samples collected on a bi-weekly basis, we are able to detect the signals of resistance and relapse much earlier than standard of care. In this project, we hope to extend this technology to a new class of breakthrough cancer medicines,” CCG.ai Chief Scientific Officer Nirmesh Patel said in a statement.
Genomics England Background
A company set up and owned by the Department of Health and Social Care to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. An infectious disease strand is being led by Public Health England.
Genomics England was formally established as a company on 17 April 2013 and was formally launched on 5 July 2013 as part of the celebrations for the 65th Birthday of the UK’s National Health Service In August 2014, the Wellcome Trust announced that it was investing £27 million in a genome-sequencing hub for Genomics England, allowing the company to become part of the Wellcome Trust Genome Campus, home to the Sanger Institute. On the same date, Prime Minister David Cameron unveiled a new partnership between Genomics England and the sequencing firm Illumina. Illumina’s services for whole genome sequencing were secured in a deal worth around £78million.
The UK Government also committed £250 million to genomics in the 2015 Spending Review, which ensures the continued role of Genomics England to deliver the project, beyond the life of the project and up to 2021.
Cambridge Cancer Genomics Background
As reported in CrunchBase, Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment.
Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England. Founded in 2016, they have raised $8.6 million in venture funding.